A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine.
Name:
Svindland et al_final.pdf
Size:
783.2Kb
Format:
PDF
Description:
Open Access publication
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Svindland, Signe CPedersen, Gabriel K
Pathirana, Rishi D
Bredholt, Geir
Nøstbakken, Jane K
Jul-Larsen, Åsne
Guzmán, Carlos A
Montomoli, Emanuele
Lapini, Giulia
Piccirella, Simona
Jabbal-Gill, Inderjit
Hinchcliffe, Michael
Cox, Rebecca J
Issue Date
2013-11
Metadata
Show full item recordAbstract
Highly pathogenic avian influenza A/H5N1 virus remains a potential pandemic threat, and it is essential to continue vaccine development against this subtype. A local mucosal immune response in the upper respiratory tract may stop influenza transmission. It is therefore important to develop effective intranasal pandemic influenza vaccines that induce mucosal immunity at the site of viral entry.Citation
A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine. 2013, 7 (6):1181-93 Influenza Other Respir VirusesAffiliation
department of vaccinology and applied microbiology, Helmholtz Centre for infection research, D38124 Braunschweig, GermanyPubMed ID
23170900Type
ArticleLanguage
enISSN
1750-2659ae974a485f413a2113503eed53cd6c53
10.1111/irv.12056
Scopus Count
The following license files are associated with this item: